Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AdAPT-001 in Refractory Solid Tumors
NCT04673942Phase 2Active, not recruiting
- Sponsor
- EpicentRx
- Start
- Mar 2021
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 2, open-label trial of AdAPT-001 in solid tumor and sarcoma (4 arms), sponsored by EpicentRx. Primary endpoints: Dose Limiting Toxicities at 28 days, Maximum Tolerated Dose at 28 days and 2 more. Started Mar 2021; status: active, not recruiting.
02
Drugs
AdAPT-001
03
Conditions
solid tumorsarcoma
Beyond the preview
Go deeper on NCT04673942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04673942.